Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain
function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration
(FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve
cognitive and mood function through modulation of leukotriene signaling and suppression of
neuroinflammation.
Phase:
Phase 1
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Michael E. DeBakey VA Medical Center Texas A&M University